Coeptis Therapeutics Holdings - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
COEP Nasdaq 2834 https://coeptistx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Coeptis Therapeutics Holdings

Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies - Mar 29th, 2023 1:45 pm
Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine - Mar 21st, 2023 11:00 am
Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling - Feb 7th, 2023 1:00 pm
Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program - Jan 31st, 2023 12:30 pm
Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program - Nov 22nd, 2022 12:00 pm
Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell - Nov 15th, 2022 12:00 pm
Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast - Nov 8th, 2022 12:00 pm
Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments - Nov 2nd, 2022 11:00 am
Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology - Sep 21st, 2022 11:00 am
Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors - May 17th, 2022 11:00 am
Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement - Apr 19th, 2022 11:00 am
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod - Apr 13th, 2022 8:05 pm
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma - Apr 13th, 2022 11:00 am